IL4 and multiple sclerosis: Consistent with a previous study in a model of multiple sclerosis [31], we found that repeated intranasal IL-4 administration did not change T-lymphocyte subpopulations or B lymphocytes in the blood (S6A–S6C Fig), suggesting that the nasal application of IL-4 has minimal systemic effects on these peripheral immune cells.